Avatrombopag for Platelet Recovery Post-UCBT in Patients With Bone Marrow Failure Disease
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age12+
SponsorAnhui Provincial Hospital
About this trial
To evaluate the efficacy and safety of Avatrombopag for platelet recovery after unrelated cord blood transplantation (UCBT) in patients with bone marrow failure disease
Eligibility criteria
Qualifiers
Age ≥12 years old, male or female;
Patients diagnosed with bone marrow failure disease including aplastic anemia (AA), Fanconi anemia (FA), paroxysmal nocturnal hemoglobinuria (PNH) and undergoing UCBT;
ECOG score ≤2;
Voluntary participation in this clinical trial, patients fully understand the trial content and sign the informed consent；
Disqualifiers
Pregnant or lactating women；
Known allergy to Avatrombopag;
A history of severe thrombotic events or known risk factors for thrombosis or active thromboembolism requiring anticoagulation;
A history of platelet dysfunction or bleeding prone disease or severe bleeding (requiring more than 2 units of red blood cell infusion or a hematocrit drop of ≥10%) within 7 days prior to screening;
Trial design
Treatments tested in this trial
- Avatrombopag
Treatment groups
40 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov